“Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Analysis of Pooled Data from up to Three Years of Treatment in Phase 2 and 3 Clinical Trials”. SKIN The Journal of Cutaneous Medicine, vol. 6, no. 6, Nov. 2022, p. s66, https://doi.org/10.25251/skin.6.supp.66.